Purchase will strengthen dermatology focus.

Nycomed offered to buy Bradley Pharmaceuticals at an equity purchase price of $346 million. It believes that this all-cash transaction, valued at $20 per share, will enhances it dermatologics business, PharmaDerm.


Nycomed USA and Bradley have a dermatology focus and have branded as well as generic drugs. “The acquisition of Bradley provides us with a unique opportunity to strengthen our dermatology expertise in the U.S. with successful products and capabilities that match ours perfectly,” notes Hakan Bjorklund, CEO of Nycomed.


“The acquisition enables us to gain critical mass in the dermatology market and provides significant momentum for further add-on investments,” Bjorklund adds. Nycomed plans to leverage its manufacturing and distribution capabilities to support the Bradley portfolio, improve customer service, and optimize the cost structure.


The transaction is expected to close in the first quarter of 2008.